Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.
Profitability
This table compares Autolus Therapeutics and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| Ernexa Therapeutics | N/A | -305.93% | -169.86% |
Volatility and Risk
Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500.
Institutional & Insider Ownership
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Autolus Therapeutics and Ernexa Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Autolus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 913.51%. Given Ernexa Therapeutics’ higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Autolus Therapeutics.
Earnings & Valuation
This table compares Autolus Therapeutics and Ernexa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autolus Therapeutics | $117.39 million | 4.04 | -$287.53 million | ($1.06) | -1.68 |
| Ernexa Therapeutics | $580,000.00 | 8.32 | -$14.08 million | ($14.35) | -0.21 |
Ernexa Therapeutics has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Autolus Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
